IP Library Granted Patent US 9,173,704
Granted Patent B2
US 9,173,704 · App. 12/488,070 · Granted Nov 3, 2015

Device and method for the ablation of fibrin sheath formation on a venous catheter

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,173,704
App. No.
12/488,070
Granted
Nov 3, 2015
Kind
B2
Abstract

An indwelling venous catheter and method capable of destroying undesirable cellular growth is provided. The catheter includes a shaft having at least one lumen and adapted to be placed inside a vein for long term use. A plurality of electrodes are positioned near a distal section of the shaft and are adapted to receive from a voltage generator a plurality of electrical pulses in an amount sufficient to cause destruction of cells in the undesirable cellular growth that have grown around the shaft. In one aspect of the invention, a probe is configured to be removably insertable into the at least one lumen and the electrodes are positioned near the distal section of the probe.

Claims (15)

1. A method of treating undesirable cellular growth on an indwelling venous catheter comprising:

connecting a voltage generator to a plurality of electrodes that are positioned on a shaft of the indwelling venous catheter;

applying a predetermined schedule of electrical pulses generated by the voltage generator between the plurality of connected electrodes while the shaft of the indwelling venous catheter is positioned inside a vessel the predetermined schedule of electrical pulses being of an amount sufficient to prevent the undesirable cellular growth around the shaft of the indwelling venous catheter and to electroporate cells of the undesirable cellular growth that may have formed around the shaft of the indwelling venous catheter; and

introducing a therapeutic agent into the electroporated cells of the undesirable cellular growth;

wherein the therapeutic. agent is formulated to cause cell death in the electroporated cells.

2. The method of claim 1 , further comprising:

receiving electrocardiogram (ECG) signals from a synchronization device, wherein generation of the electrical pulses by the voltage generator is based on the received ECG signals.

3. The method of claim 1 , wherein the therapeutic drug is a cytotoxic agent.

4. The method of claim 1 , wherein the plurality of electrodes are ring shaped and located near a distal end of the indwelling venous catheter.

5. The method of claim 1 , wherein the plurality of electrodes arc spiral shaped and located as segmented portions along a distal end of the indwelling venous catheter.

6. The method of claim 1 , wherein the predetermined schedule of electrical pulses is sufficient to cause permanent pore formation in the cellular membrane of the undesirable cellular growth around the shaft of the indwelling venous catheter.

7. The method of claim 1 , wherein the indwelling venous catheter further comprises an electrical concluding element and a surface of the indwelling venous catheter has skives or pockets filled with electrically conductive material.

8. The method of claim 1 , wherein the predetermined schedule of electrical pulses are simultaneously applied to all of the plurality of connected electrodes with alternating polarity.

9. The method of claim 1 , wherein the predetermined schedule of electrical pulses creates permanent openings in the undesirable cellular growth without creating a significant thermal effect to the undesirable cellular growth.

10. The method of claim 9 , wherein the undesirable cellular growth contains at least smooth muscle cells that will remain after the predetermined schedule of electrical pulses and will be removed by natural body processes.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Jun 8, 2023
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ANGIODYNAMICS, INC.
Reel/Frame 063940/0362 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2022
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ANGIODYNAMICS, INC.
Reel/Frame 061363/0446 →
SECURITY INTEREST Recorded Aug 31, 2022
From: ANGIODYNAMICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 061360/0668 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Jun 5, 2019
From: ANGIODYNAMICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 049371/0657 →
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2016
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ANGIODYNAMICS, INC.
Reel/Frame 040688/0540 →
SECURITY INTEREST Recorded Nov 8, 2016
From: ANGIODYNAMICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 040613/0049 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2013
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ANGIODYNAMICS, INC.
Reel/Frame 031315/0361 →
SECURITY AGREEMENT Recorded Sep 30, 2013
From: ANGIODYNAMICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 031315/0720 →
SECURITY AGREEMENT Recorded May 23, 2012
From: ANGIODYNAMICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028260/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2009
From: HOBBS, EAMONN P.; HAMILTON, WILLIAM C.
To: ANGIODYNAMICS, INC.
Reel/Frame 022850/0410 →